Literature DB >> 1451329

Immune response to tumor antigens in a patient with colorectal cancer after immunization with anti-idiotype antibody.

H Samonigg1, M Wilders-Truschnig, H Loibner, R Plot, A Rot, I Kuss, G Werner, H Stöger, M Wrann, D Herlyn.   

Abstract

An active vaccination protocol was performed on one patient with colon carcinoma as a pilot to a prospective randomized double-blind clinical trial with the vaccine SDZ SCV 106. This vaccine is an anti-idiotype goat antibody to the monoclonal antibody 17-1A, which is directed against the tumor antigen 17-1A. To study the effect of the therapy on the immune reactivity, several tests were performed to detect anti-tumor antibodies in the serum as well as in eluates of metastatic tissue. Furthermore metastases removed from the lung were examined by immunohistochemistry. The results suggest that the humoral and cellular immune reactivity against the tumor are enhanced.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1451329     DOI: 10.1016/0090-1229(92)90157-j

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  2 in total

Review 1.  Anti-idiotype and recombinant antigen in immunotherapy of colorectal cancer.

Authors:  D Herlyn; R Somasundaram; J Zaloudik; L Jacob; D Harris; M P Kieny; H Sears; M Mastrangelo
Journal:  Cell Biophys       Date:  1994

2.  Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.

Authors:  B J Kroesen; J Buter; D T Sleijfer; R A Janssen; W T van der Graaf; T H The; L de Leij; N H Mulder
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.